Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 13:54:101699.
doi: 10.1016/j.eclinm.2022.101699. eCollection 2022 Dec.

Development of the PREDS score to predict in-hospital mortality of patients with Ebola virus disease under advanced supportive care: Results from the EVISTA cohort in the Democratic Republic of the Congo

Marie Jaspard  1   2 , Sabue Mulangu  3 , Sylvain Juchet  1   2 , Beatrice Serra  1   2 , Ibrahim Dicko  1 , Hans-Joeg Lang  1 , Baweye Mayoum Baka  1 , Gaston Musemakweli Komanda  4 , Jeremie Muhindo Katsavara  4 , Patricia Kabuni  5 , Fabrice Mbika Mambu  3 , Margaux Isnard  6 , Christophe Vanhecke  7 , Alexia Letord  8 , Ibrahima Dieye  9 , Oscar Patterson-Lomba  9 , Olivier Tshiani Mbaya  3 , Fiston Isekusu  5 , Donatien Mangala  5 , Jean Luc Biampata  3 , Richard Kitenge  10 , Moumouni Kinda  1 , Xavier Anglaret  2 , Jean Jacques Muyembe  3 , Richard Kojan  1 , Khaled Ezzedine  2   11 , Denis Malvy  2   12
Affiliations

Development of the PREDS score to predict in-hospital mortality of patients with Ebola virus disease under advanced supportive care: Results from the EVISTA cohort in the Democratic Republic of the Congo

Marie Jaspard et al. EClinicalMedicine. .

Abstract

Background: As mortality remains high for patients with Ebola virus disease (EVD) despite new treatment options, the ability to level up the provided supportive care and to predict the risk of death is of major importance. This analysis of the EVISTA cohort aims to describe advanced supportive care provided to EVD patients in the Democratic Republic of the Congo (DRC) and to develop a simple risk score for predicting in-hospital death, called PREDS.

Methods: In this prospective cohort (NCT04815175), patients were recruited during the 10th EVD outbreak in the DRC across three Ebola Treatment Centers (ETCs). Demographic, clinical, biological, virological and treatment data were collected. We evaluated factors known to affect the risk of in-hospital death and applied univariate and multivariate Cox proportional-hazards analyses to derive the risk score in a training dataset. We validated the score in an internal-validation dataset, applying C-statistics as a measure of discrimination.

Findings: Between August 1st 2018 and December 31th 2019, 711 patients were enrolled in the study. Regarding supportive care, patients received vasopressive drug (n = 111), blood transfusion (n = 101), oxygen therapy (n = 250) and cardio-pulmonary ultrasound (n = 15). Overall, 323 (45%) patients died before day 28. Six independent prognostic factors were identified (ALT, creatinine, modified NEWS2 score, viral load, age and symptom duration). The final score range from 0 to 13 points, with a good concordance (C = 86.24%) and calibration with the Hosmer-Lemeshow test (p = 0.12).

Interpretation: The implementation of advanced supportive care is possible for EVD patients in emergency settings. PREDS is a simple, accurate tool that could help in orienting early advanced care for at-risk patients after external validation.

Funding: This study was funded by ALIMA.

Keywords: Ebola virus; In-hospital mortality; Outcome; Predictive score; Sub-Saharan Africa; Supportive care.

PubMed Disclaimer

Conflict of interest statement

No conflict of interest is declared by any of the authors. SM is listed as the inventor on the patent application for mAb 114, US Application No.62/087, 087 (PCT Application No.PCT/US2015/060733) related to anti-Ebola virus antibodies and their use.

Figures

Figure 1
Figure 1
Inclusion flowchart.
Figure 2
Figure 2
Kaplan Meier probability of death for PREDS individual parameters in the training sample (N = 279).
Figure 3
Figure 3
Estimated risk of death and survival probability for a low (Score 0–5), Medium (Score 6–9), or High (Score 10–13) PREDS score.
See this image and copyright information in PMC

References

    1. 10th Ebola outbreak in the Democratic Republic of the Congo declared over; vigilance against flare-ups and support for survivors must continue.https://www.who.int/news/item/25-06-2020-10th-ebola-outbreak-in-the-demo.... Accessed 21 July 2022.
    1. Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) Lancet Lond Engl. 2017;389:505–518. - PMC - PubMed
    1. Coller B-AG, Blue J, Das R, et al. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017;35:4465–4469. - PubMed
    1. Mulangu S, Dodd LE, Davey RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293–2303. - PMC - PubMed
    1. Fischer WA, Crozier I, Bausch DG, et al. Shifting the paradigm - applying universal standards of care to ebola virus disease. N Engl J Med. 2019;380:1389–1391. - PubMed